Please login to the form below
Menarini
This page shows the latest Menarini news and features for those working in and with pharma, biotech and healthcare.
NewAmsterdam Pharma and Frazier LifeSciences announce merger agreement
The proceeds from this transaction, combined with the upfront payment of $123m received from NewAmsterdam’s recently announced licensing agreement with the Menarini Group and the company’s existing cash, would
Latest news
-
The IMC unites health industry professionals to combat antibiotic resistant infections
the British Society for Antimicrobial Chemotherapy (BSAC), Menarini UK, Pfizer UK, Roche Diagnostics UK, Thermo Fisher Scientific and the UK Sepsis Trust.
-
New cancer meds and drug extensions top CHMP recommendations
This includes Adenuric, blockbuster oncology treatment Avastin (bevacizumab) from Roche; AbbVie's auto-inflammatory drug Humira (adalimumab), Menarini's gout drug Adenuric, (febuxostat), the rare disease drug for kidney disease Soliris
-
Campaigns recognised at German health comms awards
Among the winners was Schmittgall, which picked up two awards, including the disease awareness prize for its TheraKey project for Berlin Chemie, a subsidiary of Italy's Menarini.
-
Menarini launches urology campaign in Greece
PE information push includes Not Just A Moment website. Menarini is supporting a new awareness initiative to educate men about premature ejaculation.
-
Developing your patient-centric strategy
AbbVie. 4. Menarini. 5. Janssen. Source: PatientView. Nevertheless, it's worth revisiting the announcement of ViiV's birth four and a half years ago.
More from news
Approximately 4 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
Dr Reddy's, Menarini and Cipher Pharmaceuticals have acquired or licensed rights to products in South Asia, Asia Pacific (ex-Japan) and North America and Mexico, respectively. ... Menarini AP will be responsible for the clinical development, regulatory
-
Medius Deal Watch table for April 2015
120. 4SC AG/Menarini. Licensing and development agreement. Resminostat (oral HDAC) for hepatocellular carcinoma.
-
Deal Watch table for July 2013
130‡. Vivus / Berlin-Chemie (Menarini). Licence, commercialisation, supply. Spedra (avanafil) for erectile dysfunction (approved).
-
Pharma investment in Indonesia
Two years prior to its acquisition by the Italian Menarini group in Dec 2012, the Invida Group acquired 70 per cent stake of Indonesian pharmaceutical manufacturer MUGI.
-
Pharma deals during October 2012
Whilst Oxford BioTherapeutics will be responsible for the discovery activities, Menarini will lead on the manufacture and clinical development of each programme. ... Whilst no financial terms have been disclosed, a quotation from Menarini states that the
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Life wins at the Rx Club Show
Menarini. Life also picked up 6 awards of excellence in the print category for Life self-promotion and for clients Galderma and Abbott.
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
